Search results for "asta"

showing 10 items of 3213 documents

Efficacy and Tolerability of Biweekly Bevacizumab, Irinotecan, Folinic Acid and Fluorouracil Intravenous Bolus (BIFF Regimen) in Patients With Metast…

2011

Abstract Background We have extensively assessed a biweekly regimen of irinotecan plus folinic acid and fluorouracil bolus (IRIFAFU) in metastatic colorectal cancer (MCRC). Here, we report on the safety and activity of BIFF (bevacizumab plus IRIFAFU) regimen in 94 mCRC patients. Patients and Methods Bevacizumab 5 mg/kg (1 hour), and irinotecan 180 mg/m 2 (1hour) were given intravenously on day 1, 6S-folinic acid 250 mg/m 2 (2 hours), and fluorouracil 850 mg/m 2 (bolus) were given intravenously on day 2 every 2 weeks for a median of 9 cycles per patient (range, 1-12), and maintenance bevacizumab alone was delivered in 16 cases. Results Grade ≥ 3 hematologic toxicities were neutropenia (50%) …

AdultMaleRiskOncologyAntimetabolites Antineoplasticmedicine.medical_specialtyBevacizumabLeucovorinAngiogenesis InhibitorsAntibodies Monoclonal HumanizedIrinotecanFolinic acidBolus (medicine)Internal medicineBiomarkers TumorConfidence IntervalsmedicineHumansInfusions IntravenousAgedbusiness.industryGastroenterologyAntibodies MonoclonalMiddle AgedMETASTATIC COLORECTAL CANCER BEVACIZUMABmedicine.diseaseAntineoplastic Agents PhytogenicSurvival AnalysisBevacizumabIrinotecanRegimenItalyOncologyTolerabilityFluorouracilVitamin B ComplexDisease ProgressionCamptothecinFemaleFluorouracilColorectal NeoplasmsbusinessFebrile neutropeniamedicine.drugClinical Colorectal Cancer
researchProduct

Can side-specific biopsy findings predict the side of nodal metastasis in clinically localized prostate cancer? Results from a multicenter prospectiv…

2013

Background To evaluate the correlation between the side of positive biopsy (Bx) and the risk of lymph-node metastases (LNMs) on each side and to quantify the risk of contralateral LNMs in patients with unilateral positive biopsy. Methods We analyzed the outcomes of 1599 patients with complete data regarding the sides of positive Bx and LN (lymph-node). By dividing each prostate into two separate sides, we assessed the accuracy of the side-specific Bx details in determining the side of positive nodes; the area under the receiver-operating characteristic (ROC) (AUCs) was used. For patients with unilateral positive Bx, we assessed the risk of homolateral and contralateral LNMs according to the…

AdultMaleRiskmedicine.medical_specialtyProstate biopsyPelviLymph node metastasis; Pelvic lymph node dissection; Prostate biopsy; Prostate cancer; Radical prostatectomyPelvisProstate biopsyProstate cancerLymph node metastasiProstateBiopsymedicineHumansProspective StudiesProspective surveyAgedAged 80 and overProstatectomyLymph node metastasisProstate cancermedicine.diagnostic_testbusiness.industryNodal metastasisProstatic NeoplasmsLymph NodeLymphatic MetastasiGeneral MedicineMiddle Agedmedicine.diseaseRadical prostatectomySurgeryPelvic lymph node dissectionDissectionProspective Studiemedicine.anatomical_structureROC CurveOncologyLymphatic MetastasisProstatic NeoplasmLymph Node ExcisionSurgeryRadiologyLymph NodesBiopsy Large-Core NeedlebusinessBiopsy findingsHuman
researchProduct

Different effectiveness of two pastas supplemented with either lipophilic or hydrophilic/phenolic antioxidants in affecting serum as evaluated by the…

2017

Effectiveness in improving serum antioxidant status of two functional pastas was evaluated by the novel Antioxidant/ Oxidant Balance (AOB) parameter, calculated as Antioxidant Capacity (AC)/Peroxide Level ratio, assessed here for the first time. In particular, Bran Oleoresin (BO) and Bran Water (BW) pastas, enriched respectively with either lipophilic (tocochromanols, carotenoids) or hydrophilic/phenolic antioxidants extracted from durum wheat bran, were studied. Notably, BO pasta was able to improve significantly (+65%) serum AOB during four hours after intake similarly to Lisosan G, a wheat antioxidant-rich dietary supplement. Contrarily, BW pasta had oxidative effect on serum so as conve…

AdultMaleSerumAntioxidantmedicine.medical_treatmentPeroxideAntioxidantsAnalytical Chemistrychemistry.chemical_compoundYoung Adult0404 agricultural biotechnologyPhenolsmedicineHumansFood sciencePhenolsOleoresinCarotenoidTriticumchemistry.chemical_classificationABTSBranPlant ExtractsTEACMedicine (all)Human serumfood and beveragesReproducibility of Results04 agricultural and veterinary sciencesGeneral MedicineOxidants040401 food scienceCarotenoidsDurum wheat antioxidantLOX-FLSettore AGR/02 - Agronomia E Coltivazioni ErbaceeFunctional pastachemistryBiochemistryDietary SupplementsORACFemaleTroloxLisosan GOxidation-ReductionFood ScienceFood chemistry
researchProduct

Diagnostic accuracy of fecal elastase 1 assay in patients with pancreatic maldigestion or intestinal malabsorption: a collaborative study of the Ital…

2001

Several reports have indicated that fecal elastase-1 (EL-1) determination is a new, sensitive, and specific noninvasive pancreatic function test; however, very few patients with malabsorption due to small intestine diseases have been included in the previous studies. The aim of the study was to compare the diagnostic accuracy of fecal EL-1 and fecal chymotrypsin (FCT) in distinguishing between pancreatic maldigestion and intestinal malabsorption. Three groups of subjects were studied: group A included 49 patients with known cystic fibrosis (25 males, median age 5 years); group B included 43 subjects with various small intestine diseases (17 males, median age 6 years); and group C included 4…

AdultMaleSettore MED/09 - Medicina InternaAdolescentCystic FibrosisIntestinal giardiasiFecesSensitivityMalabsorption Syndromesspecificity; pancreatic insufficiency; sensitivity; malabsorption syndrome; intestinal giardiasis; cystic fibrosis; steatorrhea; fecal elastase-1: fecal chymotrypsin; celiac diseaseMalabsorption syndromeCeliac diseaseHumansintestinal giardiasisChildPancreatic ElastaseGastroenterologyInfant NewbornInfantPancreatic DiseasesReproducibility of ResultsClinical Enzyme TestsSteatorrheaIntestinal DiseasesCystic fibrosiChild PreschoolSpecificityFecal elastase-1: fecal chymotrypsinDigestionFemalePancreatic insufficiencyDigestive diseases and sciences
researchProduct

Early and late histamine release induced by albumin, hetastarch and polygeline: some unexpected findings.

2003

Objective: The perioperative use of colloidal plasma substitutes is still under discussion. We therefore conducted a prospective randomised study with three commonly used plasma substitutes to examine their histamine releasing effects in 21 volunteers. Material or subjects: 21 male volunteers were enrolled in this prospective, randomised, controlled clinical study. Endpoints were the incidence of early and late histamine release and the time course of the release kinetics. Normovolemic hemodilution technique was used with hydroxyethyl starch (n = 6), human albumin (n = 6) and polygeline (n = 9). Measurement and observation period was 240 min after the start of the plasma substitute infusion…

AdultMaleSide effectImmunologyPlasma SubstitutesBlood PressureHydroxyethyl starchPlasma SubstitutesHistamine ReleaseHydroxyethyl Starch Derivativeschemistry.chemical_compoundDouble-Blind MethodHeart RateIntensive carePolygelinemedicineHumansSerum AlbuminHetastarchAgedPharmacologyHemodilutionChemistryAlbuminHemodynamicsMiddle AgedAnesthesiaPolygelineHistaminemedicine.drugHistamineInflammation research : official journal of the European Histamine Research Society ... [et al.]
researchProduct

Ezetimibe/Simvastatin 10/20 mg versus Rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency

2010

Abstract Objective This post-hoc analysis compared the lipid-altering efficacy of Ezetimibe/Simvastatin 10/20 mg (EZ/Simva) versus Rosuvastatin 10 mg (Rosuva) in patients stratified by statin potency/dose prior to randomization. Methods Patients with elevated low-density lipoprotein cholesterol (LDL-C) despite prior statin treatment (n = 618) were randomized 1:1 to EZ/Simva 10/20 mg or Rosuva 10 mg for 6 weeks. Percent change from baseline in lipids and attainment of lipid targets were assessed within each subgroup (low potency n = 369, high potency n = 249). Consistency of the treatment effect across subgroups was evaluated by testing for treatment-by-subgroup interaction. No multiplicity …

AdultMaleSimvastatinmedicine.medical_specialtySettore MED/09 - Medicina InternaStatinRandomizationAdolescentmedicine.drug_classEndocrinology Diabetes and MetabolismHypercholesterolemiaClinical BiochemistryUrologyPharmacologyYoung AdultEndocrinologyEzetimibemedicineHumansPotencyRosuvastatinRosuvastatin Calciumlcsh:RC620-627AgedBiochemistry medicalAged 80 and overSulfonamidesSimvastatin; Ezetimibe;hypercholesterolemic;ChemistryhypercholesterolemicResearchAnticholesteremic AgentsBiochemistry (medical)nutritional and metabolic diseasesMiddle AgedEzetimibeFluorobenzeneslcsh:Nutritional diseases. Deficiency diseasesRosuvastatin CalciumPyrimidinesTreatment OutcomeSimvastatinAzetidinesFemalelipids (amino acids peptides and proteins)Ezetimibe/simvastatinHydroxymethylglutaryl-CoA Reductase Inhibitorsmedicine.drugLipids in Health and Disease
researchProduct

Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately c…

2009

SUMMARY Aims: To evaluate the efficacy of switching from a previous statin monotherapy to ezetimibe ⁄simvastatin (EZE ⁄SIMVA) 10 ⁄20 mg vs. rosuvastatin (ROSUVA) 10 mg. Methods: In this randomised, double-blind study, 618 patients with documented hypercholesterolaemia [low-density lipoprotein cholesterol (LDL-C) ‡ 2.59 and £ 4.92 mmol ⁄l] and with high cardiovascular risk who were taking a stable daily dose of one of several statin medications for ‡ 6 weeks prior to the study randomisation visit entered a 6-week open-label stabilisation ⁄screening period during which they continued to receive their prestudy statin dose. Following stratification by study site and statin dose ⁄potency, patien…

AdultMaleSimvastatinmedicine.medical_specialtyimvastatinStatinmedicine.drug_classHypercholesterolemiaCoronary Artery DiseaseGastroenterologyhypercholesterolaemicchemistry.chemical_compoundDouble-Blind MethodEzetimibeRisk FactorsInternal medicinemedicineHumansRosuvastatinRosuvastatin CalciumAgedAged 80 and overSulfonamidesbiologybusiness.industryCholesterolCholesterol LDLGeneral MedicineMiddle AgedFluorobenzenesRosuvastatin CalciumPyrimidinesTreatment OutcomeEndocrinologychemistrySimvastatinHMG-CoA reductasebiology.proteinAzetidinesDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)Ezetimibe/simvastatinHydroxymethylglutaryl-CoA Reductase Inhibitorsbusinessezetimibemedicine.drugInternational Journal of Clinical Practice
researchProduct

Physical Exercise Intensity During Submersion Selectively Affects Executive Functions

2019

Objective The intact cognitive processing capacity in highly demanding and dynamically changing situations (e.g., in extreme environmental conditions) is of central relevance for personal safety. This study therefore investigated whether underwater physical exercise (PE) affected cognitive performance by comparing these effects during underwater fin-swimming as opposed to inactivity under normal environmental conditions. Background Although acute bouts of PE can modulate cognitive performance under highly controlled and standardized laboratory conditions, no previous study has determined whether PE acutely modulates cognitive performance in non-laboratory testing conditions involving extrem…

AdultMaleSubmersion (coastal management)Human Factors and ErgonomicsPhysical exerciseNeuropsychological TestsExecutive Function03 medical and health sciencesBehavioral NeuroscienceCognition0302 clinical medicineImmersionHumansRelevance (information retrieval)SwimmingApplied PsychologyCross-Over StudiesCognition030229 sport sciencesExecutive functionsIntensity (physics)Memory Short-TermFemalePsychology030217 neurology & neurosurgeryCognitive psychologyHuman Factors: The Journal of the Human Factors and Ergonomics Society
researchProduct

Prognostic significance of DNA ploidy, S-phase fraction, and tissue levels of aspartic, cysteine, and serine proteases in operable gastric carcinoma

2000

A consecutive series of 63 untreated patients undergoing surgical resection for stage I-IV gastric adenocarcinomas (GCs) has been prospectively studied. Our purpose was to analyze the predictive relevance of DNA ploidy, S-phase fraction (SPF), and tissue levels of lysosomal proteinases cathepsin D (CD), cathepsin B (CB), cathepsin L (CL), and urokinase-type plasminogen activator (uPA) and that of the intracellular cysteine proteinase inhibitor stefin A on clinical outcome. All of the patients taking part in this study were followed up for a median of 73 months. DNA aneuploidy was present in 71% of the cases (45/63), whereas 9% of these (4/45) showed multiclonality. Both DNA ploidy and SPF w…

AdultMaleTime FactorsAdenocarcinomaS PhasePredictive Value of TestsStomach NeoplasmsBiomarkers TumorAspartic Acid EndopeptidasesHumansNeoplasm Invasivenesshumancell cycle S phase; disease association; female; histopathology; human; lymph node metastasisAgedProbabilityPloidieslymph node metastasisdisease associationSerine EndopeptidasesDNA NeoplasmMiddle AgedPrognosisSurvival AnalysisCysteine Endopeptidasescell cycle S phaseLymphatic MetastasishistopathologyFemaleFollow-Up Studies
researchProduct

Loss of the preconditioning effect of rosuvastatin during sustained therapy: a human in vivo study

2011

Studies have demonstrated that the acute administration of 3-hydroxy-3 methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors has protective effects in the setting of ischemia-reperfusion (IR). Previously, we demonstrated that a single dose of rosuvastatin prevented IR-induced endothelial dysfunction in humans through a cyclooxygenase-2-dependent mechanism. Whether the chronic administration of HMG-CoA reductase inhibitors provides similar protection remains controversial and is unknown in humans. Eighteen male volunteers were randomized to receive a single dose of rosuvastatin (20 mg) or placebo. Twenty-four hours later, endothelium-dependent, radial artery flow-mediated dilation (FMD) w…

AdultMaleTime FactorsAdolescentEndotheliumPhysiologyCoenzyme AHyperemiaPharmacologyReductaseDrug Administration ScheduleYoung Adultchemistry.chemical_compoundDouble-Blind MethodIschemiaIn vivoPhysiology (medical)medicineHumansRosuvastatinRosuvastatin CalciumOntarioAnalysis of VarianceSulfonamidesCyclooxygenase 2 Inhibitorsbiologybusiness.industryFluorobenzenesVasodilationRosuvastatin CalciumPyrimidinesmedicine.anatomical_structurechemistryCelecoxibRegional Blood FlowReperfusion InjuryRadial ArteryHMG-CoA reductasebiology.proteinCelecoxibPyrazolesHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessBlood Flow Velocitymedicine.drugAmerican Journal of Physiology-Heart and Circulatory Physiology
researchProduct